Detecting impaired motor function as early as possible after birth with the help of a standard camera linked to intelligent systems can help in diagnosing infantile conditions characterised by hypotonia: reduction or loss of active muscle movement. A research team is investigating this approach based on the work carried out on babies with spinal muscular atrophy (SMA), a rare genetic neuromuscular disorder.
In 2019, the drug Zolgensma made headline news as the world’s most expensive treatment. The price of this medicine for spinal muscular atrophy (SMA) has been set at nearly 2 million euros per injection.
